Network pharmacology combined with experimental validation further revealed that SIN can block the pathological activation of RA-FLS by inhibiting the activity of PI3K/Akt signaling pathway (Liu Q. et al., 2024). Here, AKT1 is linked to rheumatoid arthritis.